Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ALL) is distinguished by the presence of a novel fusion gene, BCR-ABL1, which arises from a reciprocal translocation between chromosomes 9 and 22, resulting in a constitutively activated ABL tyrosine kinase. Ph+ALL constitutes about 25% of patients with pre-B ALL (Pui et al, 2004) . Its incidence increases with age; nearly 50% of pre-B ALL patients aged over 50 years are Ph+ (Ravandi & Kebriaei, 2009 ). The presence of Philadelphia chromosome has been identified as a bad prognostic factor in pre-B ALL: in the pre-tyrosine kinase inhibitor (TKI) era, fewer than 25% of patients achieved long-term remission with conventional chemotherapy (Thomas et al, 2004; Rowe et al, 2005) .
Imatinib (Gleevec â ), a TKI with activity against the ABL kinase, has revolutionized the care of patients with chronic myeloid leukaemia, which is also driven by the BCR-ABL1 fusion gene. Imatinib was approved by the US Food and Drug Administration (FDA) for the treatment of Ph+ALL in 2004, followed by other, more potent, TKIs (Ravandi et al, 2010 Foa et al, 2011; Jabbour et al, 2015; Kim et al, 2015; Rousselot et al, 2016; Sasaki et al, 2016; Short et al, 2016) . The use of BCR-ABL1 TKIs appears to have significantly improved the survival in Ph+ALL, based on post-hoc comparisons between prospective clinical trials conducted before and after the introduction of this class of drugs (Thomas et al, 2004; Yanada et al, 2006; de Labarthe et al, 2007; Mizuta et al, 2011; Fielding et al, 2014) . However, to date there has been no large-scale population based study comparing the survival of Ph+ALL with Philadelphia negative research paper First published online 18 October 2017 doi: 10.1111/bjh.14953 (PhÀ) ALL in the TKI era. This is important because survival of patients on clinical trials often exceeds results seen in "real world" population-based studies, due to study exclusion criteria, disparities in the number of elderly patients who receive TKI therapy, omission of patients with central nervous system involvement, etc. Thus the apparent improvement in outcomes has awaited confirmation at the population level. The analysis of the effect of Ph+ status on outcome of B-ALL has not been feasible up until now because translocation status (by fluorescent in situ hybridization, FISH) has only been captured as a separate code in the US Surveillance, Epidemiology, and End Results (SEER) cancer registries since 2010. Thus, other studies have assessed trends in survival of ALL or acute leukaemia but have not been able to assess the effect of distinct mutations (Pulte et al, 2013) . We hypothesized that the widespread adoption of TKIs had indeed abrogated the adverse risk of Ph+ALL, and that this would be reflected in an improved survival of Ph+ALL.
In this study, we used data from the population-based US SEER cancer registries to analyse the survival of Ph+ALL and PhÀALL in patients diagnosed between 2010 and 2014 (a period during which TKI were widely used in Ph+ALL in the United States). We quantified the proportions of patients with Ph+ subtype, by racial and ethnic groups, age and sex. We also analysed the survival differences by age, sex, racial/ ethnic classification, year of diagnosis, marital status and insurance status.
Methods
Data for patients diagnosed with ALL aged ≥18 years between 1973 and 2014 (N = 10 064) were extracted from the most recent version of SEER database (Version April 2017) (SEER 2017 
Statistical analysis
The primary endpoints of the study were overall survival (OS), defined as the period from date of diagnosis to the date of death or censored at date of last contact, 31 December 2014 or 10 years after diagnosis, whichever came first. Both univariate survival analysis [Kaplan Meier (KM) curves, medians, hazard ratios and log-rank tests] and multivariate Cox regression model (adjusted hazard ratios and Wald tests) were used to evaluate the difference in OS by Ph status and other patient characteristics. Adjusted median OS estimates were derived from the direct adjusted survival probabilities from the multivariate Cox regression model (Zhang et al, 2007) . Interactions between Ph status and age (18-39 vs. 40+ years) and year of diagnosis (2010-2012 vs. 2013-2014) on OS were tested by including the interaction term in the multivariate Cox regression model. The analyses were conducted using SAS Version 9.4 (SAS Institute, Cary, NC) at a significance level of 0Á05. All tests are 2-sided.
Results
A total of 10 064 patients were diagnosed with pre-B ALL from 1973 to 2014 in SEER. Ph status was not initially recorded in the SEER database, however, from 2010 onwards, the SEER database began categorizing BCR-ABL1 (Philadelphia chromosome) positive ALL (Ph+ALL) using a separate code. A total of 2694 patients (median age 50 years, range 18-102 years) were diagnosed between 2010 and 2014, of which 2488 patients were diagnosed with PhÀALL and 206 patients with Ph+ALL (Fig 1) .
Characteristics of patients in 2010-2014 cohort
Ph+ALL patients were significantly older than those with PhÀALL (median age 53 vs. 49 years respective, P = 0Á01) (Tables I and II) ; 54Á9% were male with no sex differences between Ph+ALL and PhÀALL. Analysis of the racial/ethnic composition between Ph+ALL and PhÀALL showed a lower percentage of Hispanics in the Ph+ALL group compared to PhÀALL, with 18Á9% of Ph+ALL categorized as Hispanic compared to 35Á7% of PhÀALL. There was no significant difference in the insurance type between Ph+ALL and PhÀALL. Only 35Á4% of Ph+ALL patients were reported to be married at the time of diagnosis compared to 50Á2% of PhÀALL (P < 0Á0001).
Overall survival of patients with ALL
The OS of all patients with pre-B ALL estimated from 1973 to 2014 showed significant increase with each decade (adjusted P < 0Á001) (Fig 2): 1973 (Fig 2): -1979 [adjusted median The highest increase in median OS (6 months) was seen in the period comparing 2000-2009 to 2010-2014 . The adjusted OS estimates by period were calculated from the multivariate Cox regression model, which included age, sex, race/ethnicity, marital status at diagnosis and insurance type.
We next evaluated the survival of Ph+ALL verses PhÀALL in the 2010-2014 cohort. The median follow-up among patients who were alive at the time of analysis (N = 1516) was 19Á0 months (range: 1-59 months). Based on KM curves, the median OS between Ph+ALL [32 months, 95% CI = 18-not evaluated (NE)] and PhÀALL (27 months, 95% CI = 24-30) was not statistically significant [unadjusted hazard ratio (HR) = 1Á12, 95% CI: 0Á88-1Á42, comparing PhÀALL to Ph+ALL, Log-rank test P-value = 0Á34] (Fig 3A) . The 36-month survival rate for Ph+ALL was 46Á9% (95% CI = 36Á3-56Á9%) compared to 44Á6% (95% CI = 42Á2-47Á0%) for PhÀALL.
Trend towards better survival in later Ph+ cohorts
To evaluate the progress in the survival of Ph+ALL compared to PhÀALL with time, the OS was estimated separately for patients diagnosed between 2010 -2012 and 2013 -2014 . For 2010-2012, there was no significant difference (unadjusted HR = 0Á97, 95% CI: 0Á74-1Á29, comparing PhÀALL to Ph+ALL, Log-rank Pvalue = 0Á86) in the OS between Ph+ALL (median OS = 24Á5 months, 95% CI = 17Á0-43Á0) and PhÀALL 
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(median OS = 27, 95% CI = 23Á0-30Á0). For patients diagnosed between 2013 and 2014 period, there was a trend towards better survival for patients diagnosed with Ph+ALL (1-year survival rate: 78Á8%, 95% CI = 67Á1-86Á7%) compared to PhÀ (1-year survival rate: 69Á2%, 95% CI = 65Á5-72Á6%), although the difference was not statistically significant (unadjusted HR = 1Á45, 95% CI: 0Á93-2Á26, comparing PhÀALL to Ph+ALL, Log-rank P-value = 0Á094). Interaction test for Ph status and the period of diagnosis on OS was not significant in the multivariate model including the interaction term and other variables in Table I (P = 0Á11). Standard front line induction therapy for younger adult ALL typically involves high-dose multi-agent chemotherapy. Older patients are often unable to tolerate regimens given at standard doses and this may contribute to the very poor outcomes seen in these patients. Since TKIs are comparatively less toxic and easier to tolerate, we analysed the survival of Ph+ and PhÀALL by young adult ALL (18-39 years) and older ALL (≥40 years) patient groups ( Fig 4A, B and Table  SIII ). There was no significant difference in the OS between Ph+ALL and PhÀALL for young adults (unadjusted HR = 0Á83, 95% CI: 0Á50-1Á37, comparing PhÀALL to Ph+ALL, Log-rank P-value = 0Á46). Older adults with Ph+ALL (median OS = 32 months, 95% CI = 18Á0-43Á0) had a significantly better OS (unadjusted HR = 1Á32, 95% CI: 1Á01-1Á73, comparing PhÀALL to Ph+ALL, Log rank test P-value = 0Á037) compared to older adults with PhÀALL (median OS = 18 months, 95% CI = 17Á0-21Á0), using a univariate survival analysis. However, after adjusting for confounding variables using a multivariate Cox regression model, the difference was not statistically significant (adjusted HR = 1Á25, 95% CI: 0Á95-1Á64, comparing PhÀALL to Ph+ALL, Wald Chi-Square P-value = 0Á11). Interaction test for Ph status and age at diagnosis on OS was not significant in the multivariate model including the interaction term and other variables in Table I (P = 0Á21).
Analysis was also performed to evaluate other variables that might influence the survival for patients diagnosed with pre-B ALL. After adjusting for the covariates (age, sex, race/ ethnicity, marital status, type of insurance and year of diagnosis), only age (Wald chi-square P < 0Á001), race/ethnicity (Wald chi-square P-value = 0Á009) and insurance type (Wald chi-square P < 0Á001) significantly influenced the outcome. Increase in age, patients with Medicaid insurance and those of African-American and Hispanic ethnicity/race were associated with worse OS.
Discussion
Our study is the first to compare the survival of Ph+ALL and PhÀALL in the TKI era using a large population-based database. The use of TKIs in Ph+ALL were reported as early as 2001, however use of TKIs as a standard part of front-line induction therapy for Ph+ALL is not part of the FDA label for any of the currently approved TKIs (Druker et al, 2001; Ottmann et al, 2002; Champagne et al, 2004) . Treatment information, including TKI use, is not captured in the SEER database; however, by 2010, the use of TKIs was widespread and recommended by experts in the field and consensus guidelines (Fielding, 2010) .
Our results indicate that in the TKI era, the survival outcome of Ph+ALL is not statistically different from that of PhÀALL. Current recommendations continue to use Ph status to risk-stratify ALL patients. Our study shows that since the introduction and adoption of BCR-ABL1 TKIs for the treatment of Ph+ALL, Ph status no longer serves as a prognostic marker, but rather a predictive marker for response to TKI.
In the patients diagnosed between 2013 and 2014, there was a statistically non-significant trend towards better survival for Ph+ALL compared to PhÀALL. The follow-up in this cohort was limited, but it is possible that with longer follow-up, the survival difference would be significant. Recent years have seen an increase in the use of second-generation TKIs for treatment of Ph+ALL (dasatinib, nilotinib, ponatinib). Newer-generation TKIs offer higher response rates and earlier complete molecular response, which may confer better survival in Ph+ALL when used in place of imatinib (Ravandi et al, 2010 Foa et al, 2011; Jabbour et al, 2015; Kim et al, 2015; Rousselot et al, 2016; Sasaki et al, 2016; Short et al, 2016) . Thus the apparent improvement in survival in 2013-2014 could be a reflection of increased use of second-generation TKIs in Ph+ALL.
Currently, Ph+ adults less than 65 years of age with no substantial comorbidities who achieve complete remission with induction chemotherapy are offered allogeneic stem cell transplantation (AlloSCT), if available.In the pre-imatinib era, AlloSCT resulted in improvement in survival compared to chemotherapy alone (Cornelissen et al, 2001; Dombret et al, 2002; Avivi & Goldstone, 2003; Esperou et al, 2003; Goldstone et al, 2008) . Studies suggest that the incorporation of TKI (imatinib) into the treatment regimen for Ph+ALL patients has led to improvements in outcomes over alone and, by increasing remission rates, may have lead to an increase in the percentage of patients preceding to AlloSCT (Thomas et al, 2004; Yanada et al, 2006; Fielding et al, 2014) . A recent study showed excellent outcome for Ph+ALL patients who achieved complete molecular remission at 3 months with a combination of TKI and chemotherapy but without AlloSCT . AlloSCT could potentially be restricted to patients who do not achieve a complete molecular remission or at the time of relapse. This study shows that we have made tremendous progress in treating Ph+ALL. But, since our data does not capture the specific treatment the patients received, the relative contribution of TKIs versus AlloSCT cannot be determined. It is possible that TKI therapy would have resulted in increased complete remission enabling a higher proportion of Ph+ALL patients to undergo AlloSCT. TKIs in combination with novel agents could also have contributed to rescue of many relapsed Ph+ALL patients, enabling them to undergo AlloSCT. Also, the ability to monitor minimal residual disease in Ph+ALL using the BCR-ABL1 transcript could have contributed to early detection of relapse and hence, early intervention. Prospective randomized studies to evaluate the role of AlloSCT in Ph+ALL are warranted.
Older patients are less likely to tolerate intense chemotherapy and to undergo AlloSCT. Univariate analysis showed that the outcome of Ph+ALL in the elderly age group showed better outcome compared to PhÀALL, however the difference was not statistically significant after adjusting for co-variables. Increasingly, TKIs are being recognized as the backbone therapy for Ph+ALL, and some have called into question the need for chemotherapy, given that this disease is inherently chemoresistant, particularly in older patients. TKI-based induction regimens have shown complete response rates comparable to, or better than, cytotoxic chemotherapy-based regimens, often with lower toxicity and outpatient treatment (Vignetti et al, 2007; Foa et al, 2011; Chalandon et al, 2015; Rousselot et al, 2016) . Ultimately, dual targeting of ABL kinase with catalytic site and allosteric inhibitors, such as ABL001, may make chemotherapy unnecessary in this disease (Wylie et al, 2017) . TKI-only therapies are invariably associated with the development of resistance mutations in in ABL kinase (Foa et al, 2011) and therefore newer combinations such as TKI + blinatumomab are currently being tested [Southwestern Oncology Group (SWOG) 1318, NCT02143414].
The 2010-2014 cohort showed a worse prognosis for African-American and Hispanic patients. African Americans and Native Americans have worse prognosis compared to other ethnic groups, as shown for haematological malignancies and several other cancers (Maskarinec et al, 2011; Kahn et al, 2016; Jemal et al, 2017) . Our study shows that a lower proportion of Ph+ALL were Hispanics compared to PhÀALL. Several subtypes of ALL occur more frequently in certain races and ethnic groups. For example, a higher frequency of TCF3-PBX1 ALL is seen in African Americans (Hunger & Mullighan, 2015) . It also has been reported that African American children with ALL were significantly more likely to have higher-risk prognostic features (Pui et al, 2004; Pui & Evans, 2006) . Hispanic patients are known to have a higher proportion of PhÀlike ALL, which confer worse prognosis (Harvey et al, 2010; Hunger & Mullighan, 2015; Jain et al, 2017) . Both biological and socio-economic factors could be playing a role in the differences in outcomes seen with ethnicity/race. Patients with Medicaid insurance had a worse survival compared to patients with other insurance. This again, could be a reflection of socio-economic factors.
Age has historically been considered an important prognostic factor in pre-B ALL, including Ph+ALL (Rowe et al, 2005; Gokbuget & Hoelzer, 2006; Bassan & Hoelzer, 2011) . The increasing incidence of Ph with age in ALL was attributed to contributing a worse prognosis in elderly ALL (Pui et al, 2004; Burmeister et al, 2008; Moorman et al, 2010) . However, even with the introduction of TKIs, the prognosis of elderly Ph+ALL continues to be worse than younger Ph+ALL, suggesting the contribution of other biological factors, both cancer intrinsic and extrinsic (Gleissner et al, 2002; Rowe et al, 2005; Moorman et al, 2010) . Moreover, younger children (1-9 years) with Ph+ALL have a better prognosis than adolescents with this subtype (Arico et al, 2000) .
The proportion of Ph+ALL in the 2010-2014 SEER database was lower than expected (Ravandi & Kebriaei, 2009) . It is possible the database under-reports the Ph status of the patients (for example, some of the patients in the B-ALL NOS category may not have been tested and may have been Ph+), suggesting a potential weakness of this study.
In summary, the introduction of TKIs has resulted in significant improvement in the survival of patients with Ph+ALL. Our study highlights the need for randomized studies of AlloSCT in the TKI era and a re-evaluation of prognostic and treatment algorithms for patients with pre-B ALL.
Acknowledgement
II performed the research and wrote the paper, DY performed the research and wrote the paper, AM wrote the paper, NM wrote the paper, GY wrote the paper, KK designed the research and wrote the paper, GR designed the study, performed the research and wrote the paper.
Supporting Information
Additional Supporting Information may be found in the online version of this article: 
